Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine
Forbes Business
by Ty Roush, Forbes StaffFebruary 18, 2026
The agency previously told Moderna its application did not contain an “adequate and well-controlled” trial.
Verticals
businessfinance
Originally published on Forbes Business on 2/18/2026